teaser
- Greg Duncan, Executive Vice President, President of North American Operations
- Jean-Christophe Tellier, MD, Executive Vice President, President of European Operations
With UCB set to enter its growth phase in 2012 and building on major advances in its late-stage pipeline, UCB announced today that two new members will join the company’s Executive Committee as of July 1, 2011.
The two new members are the heads of the US and European commercial operations, respectively Greg Duncan, currently Senior Vice President and President of UCB’s North American Operations, and Jean-Christophe Tellier, joining UCB from Ipsen. These additions will allow Mark McDade, UCB’s EVP Global Operations and Chief Operating Officer to focus on UCB’s future growth markets outside the US and Europe, while driving UCB’s commercial growth strategy across all geographies. Mark will also continue to lead Business Development and maintains his global leadership of the company’s Marketing, Access and Medical Affairs functions, preparing the launch and commercialisation of the next generation of medicines from UCB’s promising late-stage pipeline, such as brivaracetam in epilepsy, epratuzumab in Lupus and Sclerostin antibody in post-menopausal osteoporosis and fracture healing.
Greg Duncan joined UCB in 2007 to lead UCB’s European Operations. He then became President of European and Emerging Market Operations until 2009 when he was appointed President of UCB’s North American operations. Greg has a degree in Economics from the State University of New York, Albany, and a MBA in Marketing and Management from the Emory University in Atlanta. He started his career in 1989, within Pfizer, where he had spent 17 years holding various managerial positions. His last position within Pfizer was as President Latin America.
Jean-Christophe Tellier is joining UCB from Ipsen where he was President & General Manager Ipsen US. His role at Ipsen was to strengthen Ipsen’s specialty care business in North America, in the areas of endocrinology and neurology. Prior to joining Ipsen in May 2009, he was Executive Vice President and Chief Commercial Officer at MacroGenics Inc, a Maryland-based biotechnology company. Jean-Christophe Tellier spent the largest part of his career at Novartis (Ciba) where he held several commercial operations roles in France, Belgium and Switzerland. Jean-Christophe Tellier is a physician specialised in rheumatology (University of Paris V, France).
